Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
162 hedge funds and large institutions have $1.22B invested in Acorda Therapeutics in 2018 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 53 increasing their positions, 43 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
23% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 43
11% more capital invested
Capital invested by funds: $1.09B → $1.22B (+$123M)
8% more funds holding
Funds holding: 150 → 162 (+12)
57% less call options, than puts
Call options by funds: $17.2M | Put options by funds: $39.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$19.2M |
| 2 |
Millennium Management
New York
|
+$13.4M |
| 3 |
FAM
Fred Alger Management
New York
|
+$9.29M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.37M |
| 5 |
Renaissance Technologies
New York
|
+$5.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$26.6M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$7.79M |
| 3 |
Morgan Stanley
New York
|
-$7.78M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$5.35M |
| 5 |
D.E. Shaw & Co
New York
|
-$5.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Parallax Volatility Advisers
San Francisco,
California
| – | -$142K | -55 | Closed |
|
|
DCM
177
Delpha Capital Management
New York
| – | -$59K | -23 | Closed |
|
178
Pacer Advisors
Malvern,
Pennsylvania
| – | -$36K | -14 | Closed |
|
|
RWA
179
Ropes Wealth Advisors
Boston,
Massachusetts
| – | -$5K | -2 | Closed |
|
|
QCG
180
Quadrant Capital Group
Cincinnati,
Ohio
| – | +$2.99K | +1 | New |
|
ACOR Hedge Fund Activity: Q1 2018 in Review
162 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2018, worth a combined $1.22B — up 11% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ACOR positions and 15 closed out — a net gain of 14 holders — while 53 added to existing stakes and 43 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $19.2M. The largest seller was Invesco, cutting an estimated $26.6M.
- 162 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2018, up from 150 in Q4 2017.
- Funds reported $1.22B of Acorda Therapeutics stock for Q1 2018, up 11% quarter-over-quarter.
- 29 funds opened new Acorda Therapeutics positions in Q1 2018 and 15 closed out, a net change of +14 holders.
- The largest Acorda Therapeutics buyer in Q1 2018 was HealthCor Management, an estimated $19.2M added.
- The largest Acorda Therapeutics seller in Q1 2018 was Invesco, an estimated $26.6M sold.
Based on aggregated 13F filings for Q1 2018.